[go: up one dir, main page]

UY37381A - COMPOUNDS THAT INHIBIT PROTEASES 3C AND 3CL AND METHODS OF USE OF THE SAME - Google Patents

COMPOUNDS THAT INHIBIT PROTEASES 3C AND 3CL AND METHODS OF USE OF THE SAME

Info

Publication number
UY37381A
UY37381A UY0001037381A UY37381A UY37381A UY 37381 A UY37381 A UY 37381A UY 0001037381 A UY0001037381 A UY 0001037381A UY 37381 A UY37381 A UY 37381A UY 37381 A UY37381 A UY 37381A
Authority
UY
Uruguay
Prior art keywords
compounds
methods
same
inhibit proteases
proteases
Prior art date
Application number
UY0001037381A
Other languages
Spanish (es)
Inventor
Qi Jin
Janos Botyanszki
G CATALANO John
Yoke Chong Pek
D Dickson Hamilton
Anna Leivers
Xiangmin Liao
Andrew Maynard
John Miller
Wing-Fai TAI Vincent
Reema Thalji
Brad Shotwell John
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY37381A publication Critical patent/UY37381A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos, específicamente inhibidores de proteasas, más específicamente inhibidores de proteasas 3C y 3CL, para el tratamiento de infecciones virales, y métodos de preparación y uso de tales compuestos.Compounds, specifically protease inhibitors, more specifically 3C and 3CL protease inhibitors, for the treatment of viral infections, and methods of preparing and using such compounds.

UY0001037381A 2016-08-30 2017-08-28 COMPOUNDS THAT INHIBIT PROTEASES 3C AND 3CL AND METHODS OF USE OF THE SAME UY37381A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381560P 2016-08-30 2016-08-30
US201662382410P 2016-09-01 2016-09-01

Publications (1)

Publication Number Publication Date
UY37381A true UY37381A (en) 2018-03-23

Family

ID=59966793

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037381A UY37381A (en) 2016-08-30 2017-08-28 COMPOUNDS THAT INHIBIT PROTEASES 3C AND 3CL AND METHODS OF USE OF THE SAME

Country Status (3)

Country Link
TW (1) TW201817714A (en)
UY (1) UY37381A (en)
WO (1) WO2018042343A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818691A (en) * 2018-08-09 2020-02-21 中国科学院上海药物研究所 Ketoamide compound and its preparation method, pharmaceutical composition and use
CA3166596A1 (en) * 2020-01-31 2021-08-05 Hong Liu Pharmaceutical use of ketoamide-based compound
TW202202167A (en) 2020-03-26 2022-01-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 Medical use
JP2023519585A (en) 2020-03-26 2023-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Cathepsin inhibitors to prevent or treat viral infections
WO2021207729A1 (en) * 2020-04-10 2021-10-14 Mubarak Kamal Khan Compositions and methods for modulating ace2 receptor
WO2021206877A1 (en) * 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CA3180177A1 (en) * 2020-05-08 2021-11-11 The Board Of Trustees Of The Leland Stanford Junior University Protease inhibitors for treatment or prevention of coronavirus disease
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CN116685576A (en) * 2020-06-09 2023-09-01 美商帕迪斯生物科学公司 Cysteine protease inhibitors and methods of use thereof
US20230339930A1 (en) 2020-07-11 2023-10-26 Pfizer Inc. Antiviral Heteroaryl Ketone Derivatives
GB2607514B (en) 2020-07-20 2023-06-21 Enanta Pharm Inc Functionalized peptides as antiviral agents
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN116829571A (en) 2020-11-23 2023-09-29 英安塔制药有限公司 Novel spiral pyrrolidine derived antiviral drugs
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CA3173333A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US20240083845A1 (en) * 2020-12-18 2024-03-14 Heptares Therapeutics Limited Sars-cov-2 mpro inhibitor compounds
GB202107385D0 (en) * 2021-05-24 2021-07-07 Heptares Therapeutics Ltd Sars-cov-2 mpro inhibitor compounds
WO2022208262A1 (en) * 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
TW202304859A (en) * 2021-04-01 2023-02-01 美商普姆治療公司 Sars-3cl protease inhibitors
FI4122926T3 (en) * 2021-04-14 2025-07-23 Shionogi & Co Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
KR20240124438A (en) 2021-04-16 2024-08-16 푸지엔 에이키링크 바이오테크놀로지 컴퍼니 리미티드 Ring-modified proline short peptide compound and use thereof
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
WO2022265577A2 (en) * 2021-06-15 2022-12-22 Agency For Science, Technology And Research Coronavirus enzyme modulators, methods of synthesis and uses thereof
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
CN113773259A (en) * 2021-07-14 2021-12-10 上海药明康德新药开发有限公司 Virus main protease inhibitor and preparation method and application thereof
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023003610A1 (en) * 2021-07-23 2023-01-26 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
CN114149415A (en) * 2021-07-26 2022-03-08 中国药科大学 Peptide-like compound and derivative, preparation method, pharmaceutical composition and application thereof
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023009187A1 (en) * 2021-07-29 2023-02-02 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
CN117836272B (en) * 2021-08-02 2025-02-28 北京华益健康药物研究中心 3CL protease small molecule inhibitors for treating or preventing coronavirus infection and uses thereof
JP7735531B2 (en) * 2021-09-09 2025-09-08 広東衆生睿創生物科技有限公司 Ketoamide derivatives and their uses
WO2023043816A1 (en) * 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023044171A1 (en) * 2021-09-20 2023-03-23 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
EP4410788A4 (en) * 2021-09-30 2025-02-26 Shanghai Institute of Materia Medica, Chinese Academy of Sciences CYANIDE COMPOUND AND PRODUCTION PROCESS AND USE THEREOF
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12145941B2 (en) 2021-12-08 2024-11-19 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN116239649A (en) * 2021-12-08 2023-06-09 浙江大学智能创新药物研究院 Compound and composition for virus 3CL protease inhibitor and application thereof
CN115583984A (en) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 Azaspiro compound and its preparation method, pharmaceutical composition and application
WO2023149982A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars
CN114957383B (en) * 2022-04-01 2024-12-31 中国科学院上海药物研究所 Peptidomimetic compound, preparation method, pharmaceutical composition and use thereof
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2024078294A1 (en) * 2022-10-13 2024-04-18 广东众生睿创生物科技有限公司 Amorphous form of ketoamide derivative, and preparation method therefor
WO2024078302A1 (en) * 2022-10-13 2024-04-18 广东众生睿创生物科技有限公司 Crystal form of ketoamide derivative and preparation method therefor
US20240228535A1 (en) * 2022-11-22 2024-07-11 Merck Sharp & Dohme Llc Protease inhibitors for treating or preventing coronavirus infection
WO2024131615A1 (en) * 2022-12-23 2024-06-27 广东众生睿创生物科技有限公司 Pharmaceutical composition for treating or relieving covid-19 and formulation comprising same
WO2025071482A1 (en) * 2023-09-26 2025-04-03 Agency For Science, Technology And Research (A*Star) 3cpro inhibitors and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
CA2850003C (en) * 2011-09-27 2020-01-07 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses

Also Published As

Publication number Publication date
TW201817714A (en) 2018-05-16
WO2018042343A3 (en) 2018-04-19
WO2018042343A2 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
UY37381A (en) COMPOUNDS THAT INHIBIT PROTEASES 3C AND 3CL AND METHODS OF USE OF THE SAME
CO2021007068A2 (en) Iraq degraders and uses thereof
MX2023004593A (en) Tyk2 inhibitors and uses thereof.
DOP2019000180A (en) INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
ZA201903984B (en) Methods of using thermostable serine proteases
EA201891024A1 (en) TANK-BINDING KINASE INHIBITOR COMPOUNDS
CR20160500A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
BR112019012342A2 (en) il-11 antibodies
MX2022007841A (en) Smarca degraders and uses thereof.
BR112019012343A2 (en) il-11ra antibodies
ECSP17023281A (en) MK2 INHIBITORS AND THEIR USES
MX2017005920A (en) Anti-tim3 antibodies and methods of use.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018001890A (en) Bicyclic compounds as atx inhibitors.
CL2016001231A1 (en) Autotaxin Inhibitor Compounds
CY1124338T1 (en) 3-PHOSPHOGLYCERATE DEHYDROGENATION INHIBITORS AND THEIR USES
CL2015001377A1 (en) Inhibitors of bmi-1 reverse substituted primidins
MX2015011514A (en) HETEROARILO COMPOUNDS AND ITS USES.
MX383880B (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USING THEM.
CR20150524A (en) HETEROARILO COMPOUNDS AND ITS USES
MX2019013645A (en) KINASE INHIBITORS AND USES THEREOF.
MX2022000053A (en) SESTRIN-GATOR2 INTERACTION MODULATORS AND THEIR USES.
MX2022007436A (en) Autotaxin inhibitors and uses thereof.
CL2020003083A1 (en) Masp-2 inhibitors and methods of use
CL2015002897A1 (en) Bace1 inhibitors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230626